Does UNCY pay a dividend and is it safe?

Unicycive Therapeutics Inc. (UNCY) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / UNCY / dividends

IMUX (33) OKUR (34) TLSA (47) EQ (31) ⌘ Pro Terminal →

Unicycive Therapeutics Inc. (UNCY) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.49 -6.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.44

Unicycive Therapeutics Inc. (UNCY) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $104.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on UNCY Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is UNCY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Unicycive Therapeutics Inc. (NASDAQ: UNCY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.49 (-6.68% 1D, market cap $104.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, UNCY ranks #764 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does UNCY compare to IMUX and OKUR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), UNCY carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMUX (Immunic Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $102.5M) and OKUR (OnKure Therapeutics Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $106.1M). Among the 5-stock peer group, UNCY leads on earnings multiple (N/A) while UNCY leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for UNCY?

▼

Per UNCY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001766140), Unicycive Therapeutics Inc. generated $82.6M in revenue (-8.1% YoY), -$26.6M in net income, and -$31.3M in free cash flow against $49.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.44 (-1.39%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-12% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for UNCY)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY UNCY SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (29% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 40.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.05-13.3% Next Q

Q2 (-2Q)

Grade E$3.51+2% Next Q

Q3 (-1Q)

Grade E$3.58-2.5% Next Q

Current

Grade E$3.49-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a UNCY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While UNCY currently carries a cautious 31/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.50) and Max Pain ($3.66) forces dealer call-delta covering toward $9.18.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $UNCY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “UNCY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring UNCY)

✓Walkthrough of UNCY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

UNCY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -56.27%⚡ TESTING RESISTANCE

2026-11-03O $3.81H $3.81L $3.49C $3.49VOL 1.30M

RES: $3.75SUP: $3.09SMA50: $4.50SMA200: $6.09

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

UNCY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 UNCY Butterfly Map → + Track UNCY →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -8.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on UNCY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for UNCY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for UNCY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (UNCY)

Health Care Rank #764 of 1015 ⚔️ IMUX vs UNCY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (UNCY vs. IMUX, OKUR, TLSA, EQ)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Unicycive Therapeutics Inc. (UNCY) ranks #764 by composite RQD confidence (31/100, grade E) and #646 by equity capitalization ($104.2M). Within this direct 5-issuer industry benchmark cohort, UNCY leads on earnings valuation at N/A trailing P/E, while UNCY leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TLSA currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with UNCY at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
UNCY ACTIVE Unicycive Therapeutics Inc.	E	31/100	—	—	-35.0%	-6.68%	$104.2M	Benchmark Subject
IMUX Immunic Inc.	E	33/100	—	—	-35.0%	-2.26%	$102.5M	/imux-vs-uncy →
OKUR OnKure Therapeutics Inc. (Class A)	E	34/100	—	—	-35.0%	-1.14%	$106.1M	/okur-vs-uncy →
TLSA Tiziana Life Sciences Ltd.	D	47/100	—	—	—	-16.25%	$101.8M	/tlsa-vs-uncy →
EQ Equillium Inc.	E	31/100	—	—	-35.0%	+0.73%	$107.4M	/eq-vs-uncy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001766140 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Unicycive Therapeutics Inc. (UNCY) reported GAAP revenue of $82.6M (-8.1% vs. FY2024 revenue of $89.9M , and +12144.1% cumulative change since FY2023) , GAAP net income of -$26.6M, operating cash flow of -$31.3M, and free cash flow of -$31.3M (-9.4% YoY). On the balance sheet, UNCY closed FY2025 with $49.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$82.6M	-$26.6M	-$31.3M	-$31.3M	$49.1M	—
FY2024 (FY)	2024-12-31	$89.9M	-$36.7M	-$28.6M	-$28.6M	$31.7M	—
FY2023 (FY)	2023-12-31	$675.0K	-$30.5M	-$18.3M	-$18.3M	—	—

3. UNCY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is UNCY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does UNCY compare to IMUX and OKUR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for UNCY?

Where is UNCY trading relative to its 50-day, 200-day, and 52-week technical levels?

UNCY last traded at $3.49 (-6.68% on volume of 2,235,121 shares), positioning the stock -22.44% below its 50-day simple moving average ($4.50) and -42.69% below its 200-day simple moving average ($6.09). Across its 52-week range of $3.35 to $8.74, UNCY sits at the 2.6% percentile with a 14-day RSI of 40.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.05 to $3.93).

Direct Sub-Reports: UNCY RQD Cockpit UNCY 12M Forecast UNCY Earnings & Move UNCY Dividends & DRIP UNCY Insiders & 13F UNCY Whale Options UNCY Profit Sankey UNCY News & Why

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

UNCY — Unicycive Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Unicycive Therapeutics Inc. (UNCY) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.49 (-6.68% 1D, market capitalization $104.2M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Unicycive Therapeutics Inc. (UNCY) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile identifies a market capitalization of $0.1B. Revenue is reported as — in FY 2025 and FY 2024 (), indicating no meaningful commercial revenue in those periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Unicycive Therapeutics Inc. (UNCY) reported $82.6M in annual revenue (up from $89.9M in FY2024, -8.1% YoY) and -$26.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($675.0K revenue, -$30.5M net income) through FY2025, UNCY scaled operating cash flow to -$31.3M and free cash flow to -$31.3M, backed by $49.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.35 – $8.74 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the provided sources. The only sector context available is the Health Care sector and Biotechnology: Pharmaceutical Preparations industry classification.

Key Question #1: Can UNCY sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $82.6M and free cash flow of -$31.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is UNCY's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

UNCY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Unicycive Therapeutics Inc. (UNCY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to UNCY Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Yahoo Finance report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Morningstar • 1d ago

UNCY Deadline Alert: SueWallSt Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of Securities Class Action Deadline on November 2, 2026

Morningstar report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Zacks Investment Research • 1d ago

Should I buy Unicycive Therapeutics (UNCY)

Zacks Investment Research report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 1d ago

Unicycive Therapeutics(UNCY) Stock Options Chain | Quotes & News

Moomoo report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stocktwits • 1d ago

UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time?

Stocktwits report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The National Law Review • 1d ago

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY)

The National Law Review report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Unicycive Therapeutics (Nasdaq:UNCY) - Stock Analysis

Simply Wall St report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 2d ago

Unicycive Therapeutics, Inc. Estimates – NASDAQ:UNCY

TradingView report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

UNCY Bull vs. Bear Conversation Board — What's Your Call at $3.49?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON UNCY 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $4.68 (+25.1%)

📌 Pinned Debate

Balance sheet pillar scores 10/20 with Altman Z 2.5 and Debt/Equity 0.5, and cash of $29.2M is reported at FY 2025, so leverage is not

Don't sleep on UNCY's setup in Health Care. Balance sheet pillar scores 10/20 with Altman Z 2.5 and Debt/Equity 0.5, and cash of $29.2M is reported at FY 2025, so leverage is not the primary weakness.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (31/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

Both sides have a point here — UNCY's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $3.18 (-15.0%)

Spot @ $3.74

Fundamental Cash Engine scores 4/20 with ROIC of -35% and FCF yield of 0%, while FY 2025 free cash flow was -$31.3M against a $106.1M m

Sitting on the sidelines or leaning short UNCY above $3.74. Fundamental Cash Engine scores 4/20 with ROIC of -35% and FCF yield of 0%, while FY 2025 free cash flow was -$31.3M against a $106.1M market capitalization.. Until Fundamental Cash Engine (4/20) and FCF yield (0.0%) inflect higher, upside is capped near $8.74.